Global Cloud-Based Drug Discovery Platform Industry to Achieve 12.6% CAGR, Poised at US$ 7,529.59 Million Valuation by 2032 | FMI Insights - News Summed Up

Global Cloud-Based Drug Discovery Platform Industry to Achieve 12.6% CAGR, Poised at US$ 7,529.59 Million Valuation by 2032 | FMI Insights


The Global Cloud-Based Drug Discovery Platform Industry is poised for unprecedented growth, riding on a robust Compound Annual Growth Rate (CAGR) of 12.6% projected throughout the forecast period. Moreover, the cloud-based drug discovery platform is flexible to offer end-users to customize it according to their projects. Global Cloud Based Drug Discovery Platform Industry DynamicsData management is a critical issue for the pharmaceutical industry. Cloud-based drug discovery platform runs at zero lag time, saving time and giving real-time access to users. https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1591Global Cloud Based Drug Discovery Platform Industry Key Players:Some of the key players operating in the Global Cloud Based Drug Discovery Platform Industry IBM Corp, Accenture PLC, BioXcel Corporation, Cloud Pharmaceuticals, Inc., WuXi AppTec (Shanghai) Co., Ltd., Dassault Systemes BIOVIA Ltd.


Source: The North Africa Journal February 02, 2024 11:32 UTC



Loading...
Loading...
  

Loading...

                           
/* -------------------------- overlay advertisemnt -------------------------- */